A new platform for nano-therapy against prostate cancer based on photo-ablation, using imaging and monitoring

PROJECT COST:

507 858 $

PRIMA CONTRIBUTION:

214 256 $

PROJECT DETAILS:

A novel therapeutic approach for prostate cancer has been developed using a carbon nanotube platform based on multi-walled carbon nanotubes (MWCNTs). This technology is designed to selectively target and destroy cancer cells and has the potential to become a standard treatment for prostate cancer. In addition, it may be adapted to treat other solid tumors, including thyroid and breast cancer.

The treatment relies on the intrinsic and unique optical–thermal properties of MWCNTs. Upon light irradiation, the nanotubes efficiently absorb energy and generate high localized temperatures, leading to rapid and selective destruction of cancer cells while minimizing damage to surrounding healthy tissue.

The preclinical results obtained in this project will support the commercial development of the technology by Guzzo Nano Research, enabling company growth, and the recruitment of highly qualified personnel. For the Jewish General Hospital Foundation of Montreal, this collaboration will highlight its role in supporting the creation and development of start-ups aimed at commercializing innovative technologies for the benefit of Quebec’s health-care system and patients. This project will also contribute to the training of two highly qualified personnel.